Ex vivo Boosted Immune Cell Therapy for Canine Hepatic Disease

다국어 초록 (Multilingual Abstract)

A 12-year-old male American Cocker Spaniel was diagnosed with a type of chronic hepatits (CH) called cholangioheaptits. Routine supportive medication was administered to the patient, and ex vivo boosted immune cell (EBI-C) therapy was used for the treatment. A histopathologic examination of the liver 19 months later revealed that the cholangiohepatitis had progressed to cholangiocarcinoma.
The medication and immune cell therapy was maintained. Two months after the new diagnosis, the patient’s state worsened, and the dog died 635 days after the first visit. EBI-C therapy is a type of immunotherapy, where immune cells are isolated from the patient’s peripheral blood mononuclear cells, expanded ex vivo, and then infused into the patient intravenously every two weeks. EBI-Cs (mean: 2.78 × 108 cells) were obtained 38 times and infused every two weeks. Most EBI-C were T-lymphocytes (99.24% of total EBI cells). T-lymphocytes produce large interferon (IFN)-γ, and IFN-γ inhibits liver fibrosis in dogs with CH. Moreover, in bile duct cancer, an increase in T-lymphocytes correlates with decreasing tumor invasion and metastasis. Thus, we propose that EBI-C therapy is applicable as a new supportive therapy for canine liver disease if other treatments like drug medication, surgery, or radiation are unavailable.

참고문헌 (Reference)

1 van den Ingh TS, "WSAVA Standards for clinical and histological diagnosis of canine and feline liver diseases" Elsevier 85-101, 2006

2 Trigo FJ, "The pathology of liver tumours in the dog" 92 : 21-39, 1982

3 Oshikiri T, "Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response" 84 : 224-228, 2003

4 Poldervaart JH, "Primary hepatitis in dogs : a retrospective review(2002-2006)" 23 : 72-80, 2009

5 Higuchi R, "Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery : report of a case" 36 : 559-562, 2006

6 Rockey DC, "Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury : implications for treatment of hepatic fibrosis" 42 : 660-670, 1994

7 Baroni GS, "Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis" 23 : 1189-1199, 1996

8 Rockey DC, "Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma" 16 : 776-784, 1992

9 Leen AM, "Improving T cell therapy for cancer" 25 : 243-265, 2007

10 Favier RP, "Idiopathic hepatitis and cirrhosis in dogs" 39 : 481-488, 2009

11 Bolkenius U, "Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells" 325 : 1264-1270, 2004

12 Center SA, "Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs" 66 : 330-341, 2005

13 Strombeck DR, "Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis : 151 cases(1977-1985)" 193 : 1109-1113, 1988

14 Czaja AJ, "Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis" 40 : 646-652, 2004

15 Takahashi R, "Current status of immunotherapy for the treatment of biliary tract cancer" 9 : 1069-1072, 2013

16 Nakakubo Y, "Clinical significance of immune cell infiltration within gallbladder cancer" 89 : 1736-1742, 2003

17 Bexfield NH, "Chronic hepatitis in the English springer spaniel: clinical presentation, histological description and outcome" 169 : 415-, 2011

18 Dill-Macky E, "Chronic hepatitis in dogs" 25 : 387-398, 1995

19 Strombeck DR, "Chronic active hepatitis in the dog" 173 : 380-386, 1978

20 Gatto M, "Cholangiocarcinoma : update and future perspectives" 42 : 253-260, 2010

21 Patel T, "Cholangiocarcinoma" 3 : 33-42, 2006

22 Patnaik AK, "Canine hepatic neoplasms : a clinicopathologic study" 17 : 553-564, 1980

23 Andersson M, "Breed, sex and age distribution in dogs with chronic liver disease : a demographic study" 32 : 1-5, 1991

24 Bexfield NH, "Breed, age and gender distribution of dogs with chronic hepatitis in the United Kingdom" 193 : 124-128, 2012

25 Raffan E, "Ascites is a negative prognostic indicator in chronic hepatitis in dogs" 23 : 63-66, 2009

26 Weng HL, "Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis" 7 : 42-48, 2001

27 Kanemoto H, "American Cocker Spaniel chronic hepatitis in Japan" 27 : 1041-1048, 2013

28 Rosenberg SA, "Adoptive cell transfer : a clinical path to effective cancer immunotherapy" 8 : 299-308, 2008

29 Rosenberg SA, "Adoptive cell therapy for the treatment of patients with metastatic melanoma" 21 : 233-240, 2009

30 June CH, "Adoptive T cell therapy for cancer in the clinic" 117 : 1466-1476, 2007